Dr. Borghaei is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Cottman Ave
# Fox
Philadelphia, PA 19111Phone+1 215-728-6900Fax+1 215-728-3639
Summary
- Dr. Hossein Borghaei is an oncologist in Philadelphia, PA and is affiliated with multiple hospitals in the area, including Temple University Hospital and Fox Chase Cancer Center-American Oncologic Hospital. He received his medical degree from Philadelphia College of Osteopathic Medicine and has been in practice 21 years. He specializes in hematologic oncology and thoracic cancer and is experienced in immunotherapy, non-small cell lung cancer, urologic oncology, biomedical research, and combined modality therapy.
Education & Training
- Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
- Graduate HospitalResidency, Internal Medicine, 1997 - 2000
- Philadelphia College of Osteopathic MedicineClass of 1996
Certifications & Licensure
- PA State License 1997 - 2024
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer Start of enrollment: 2007 Jul 05
- Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
- Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer Start of enrollment: 2011 Oct 20
- Join now to see all
Publications & Presentations
PubMed
- 685 citationsSotorasib for Lung Cancers with KRAS p.G12C Mutation.Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy, Timothy J. Price, Gerald Steven Falchook
The New England Journal of Medicine. 2021-06-04 - 1642 citationsNivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.Matthew D. Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, B. Zurawski, Sang-We Kim
The New England Journal of Medicine. 2019-09-28 - 353 citationsNivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.Naiyer A. Rizvi, Matthew D. Hellmann, Julie R. Brahmer, Rosalyn A. Juergens, Hossein Borghaei
Journal of Clinical Oncology. 2016-09-27
Press Mentions
- Should First-Line Dual Checkpoint Blockade Be Used for NSCLC with Specific Mutations?October 24th, 2024
- Warning on Use of Sotorasib After ICI in Lung CancerJune 1st, 2023
- Pleural, Pericardial Effusion cfDNA Detects Actionable EGFR MutationsJanuary 19th, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: